A Phase 3 interventional study of CT-P13 SC Auto-Injector and Placebo Auto-Injector in Moderately to Severely Active Rheumatoid Arthritis, sponsored by Celltrion. Completed at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Celltrion · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Arthritis, Rheumatoid by Celltrion — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Celltrion.
Among the 15 studies in Arthritis, Rheumatoid by Celltrion, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 10 in phase 3, and was the 15th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →None of the 15 studies in Arthritis, Rheumatoid by Celltrion is open now. The open studies under Arthritis, Rheumatoid, anywhere →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 286 across the 12 interventional studies, 300 across the 3 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.
1 of the studies in Arthritis, Rheumatoid by Celltrion that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05866614CelltrionA Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Arthritis, Rheumatoid by Celltrion, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
[Main Inclusion Criteria]
[Main Exclusion Criteria]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CT-P13 SC(Subcutaneous) Auto-Injector
Biological: CT-P13 SC Auto-Injector
Placebo Auto-Injector
Biological: Placebo Auto-Injector
Subcutaneous(SC) Injection
Subcutaneous(SC) Injection
Proportion of patients achieving clinical response according to the ACR20 criteria at Week 12
To demonstrate superiority of CT P13 SC over Placebo in terms of efficacy as determined by clinical response according to the American College of Rheumatology (ACR) definition of a 20% improvement (ACR20) at Week 12
Time frame: Week 0 ~ Week 12
Change from baseline in HAQ-DI at Week 12
Difference in mean change from baseline in HAQ-DI between treatment groups (CT-P13 SC and Placebo)
Time frame: Week 0 ~ Week 12
Evaluate Pharmacokinetics of CT-P13 SC
Serum concentration of infliximab
Time frame: Up to 52 Weeks
Evaluate Safety of CT-P13 SC
* Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 * All reported terms of AEs will be coded to system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities (MedDRA) and severity grading of AEs will be recorded according to the CTCAE Version 5.0
Time frame: Up to 52 Weeks
Ran from Jan 2025 to primary completion in Jun 2025, 5 months.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 5 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.